According to a biographical note "prior to founding CMPI, he was senior fellow at the Manhattan Institute working on research and activities surrounding health care issues. Dr. Goldberg's current research interests include the impact of price controls on biopharmaceutical innovation, FDA reform, the future impact of medical progress and new medical technologies, the enemies of medical innovation, and the impact of government regulation on health care quality."
His biographical note states that he "has testified before the Senate Special Committee on Aging, the Senate Small Business Committee, and the House Commerce Committee. He has written for The Wall Street Journal, The Washington Post, The Los Angeles Times, National Review Online, and The Weekly Standard, and he writes regularly for The Washington Times."
Articles and Resources
Related SourceWatch Articles
- "Nationally Recognized Researchers Provide First Economic Projections of Social Value of Treatments That Delay Onset of Alzheimer's Disease", Media Release, May 14, 2007.
|This article is a stub. You can help by expanding it.|